This protocol addresses advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) in patients harbouring an EGFR exon 20 insertion mutation — a molecularly distinct subgroup. EGFR exon 20 insertion mutations represent the third most common group of EGFR mutations, occurring in approximately 2% of all patients with NSCLC and in 4–12% of patients with any EGFR mutation.
Management of this mutation-defined population includes specific targeted agents indicated as subsequent therapy options for patients who have not previously received them. The complete agent selection, sequencing, and eligibility criteria are detailed in the full protocol.
EGFR exon 20 insertion mutations are the third most common group of EGFR mutations; these heterogenous mutations occur in approximately 2% of patients with NSCLC and 4% to 12% of patients with EGFR mutations.
The NCCN NSCLC Panel recommends single-agent amivantamab-vmjw or sunvozertinib (if available) as subsequent therapy options (if not given previously) for patients with EGFR exon 20 insertion mutation-positive advanced or metastatic NSCLC.
View source ↗